45 results
424B5
BLPH
Bellerophon Therapeutics, Inc.
31 May 23
Prospectus supplement for primary offering
4:40pm
with Pulmonary Fibrosis (PH-PF), which includes idiopathic interstitial pneumonias, chronic hypersensitivity pneumonitis, occupational and environmental lung … the environmental and the expiratory concentration of nitrogen dioxide associated with use of the INOpulse delivery system. Both studies found that the nitrogen
8-K
EX-10.1
fjtbxa0r8ujqc48fxmqu
17 Jul 20
Entry into a Material Definitive Agreement
5:01pm
424B5
a3xp0k
17 Jul 20
Prospectus supplement for primary offering
5:01pm
8-K
EX-1.1
tp5um
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
424B5
bo9x4ifn95litzku nje
20 May 20
Prospectus supplement for primary offering
4:03pm
424B5
bric7
20 May 20
Prospectus supplement for primary offering
4:02pm